127 related articles for article (PubMed ID: 24355418)
1. Cisplatin-ineligible and chemotherapy-ineligible patients should be the focus of new drug development in patients with advanced bladder cancer.
Sonpavde G; Galsky MD; Latini D; Chen GJ
Clin Genitourin Cancer; 2014 Apr; 12(2):71-3. PubMed ID: 24355418
[No Abstract] [Full Text] [Related]
2. Does neoadjuvant cisplatin-based chemotherapy improve the survival of patients with locally advanced bladder cancer: a meta-analysis of individual patient data from randomized clinical trials. Advanced bladder cancer overview collaboration.
Scher HI
J Urol; 1995 Nov; 154(5):1970. PubMed ID: 7563394
[No Abstract] [Full Text] [Related]
3. [Neoadjuvant cisplatin chemotherapy and radical cystectomy in bladder carcinoma].
Dunst J
Strahlenther Onkol; 1996 Aug; 172(8):463-4. PubMed ID: 8765352
[No Abstract] [Full Text] [Related]
4. First-line treatment of metastatic disease: cisplatin-ineligible patients.
Cathomas R; De Santis M; Galsky MD
Hematol Oncol Clin North Am; 2015 Apr; 29(2):329-40, x. PubMed ID: 25836938
[TBL] [Abstract][Full Text] [Related]
5. Formulas calculating creatinine clearance are inadequate for determining eligibility for Cisplatin-based chemotherapy in bladder cancer.
Raj GV; Iasonos A; Herr H; Donat SM
J Clin Oncol; 2006 Jul; 24(19):3095-100. PubMed ID: 16809735
[TBL] [Abstract][Full Text] [Related]
6. Neoadjuvant cisplatin for advanced bladder cancer.
Advanced Bladder Cancer Overview Collaboration
Cochrane Database Syst Rev; 2000; (2):CD001426. PubMed ID: 10796791
[TBL] [Abstract][Full Text] [Related]
7. Chemotherapy for advanced transitional cell carcinoma of the urothelium: cisplatin or carboplatin?
Culine S
Eur Urol; 2007 Jul; 52(1):9-10. PubMed ID: 17239527
[No Abstract] [Full Text] [Related]
8. First-Line Atezolizumab Effective in Bladder Cancer.
Cancer Discov; 2016 Aug; 6(8):OF7. PubMed ID: 27329924
[TBL] [Abstract][Full Text] [Related]
9. Bladder cancer: Cisplatin response is modulated by AR activity.
Fenner A
Nat Rev Urol; 2016 Aug; 13(8):437. PubMed ID: 27349366
[No Abstract] [Full Text] [Related]
10. Adjuvant chemotherapy is possibly beneficial for locally advanced or node-positive bladder cancer.
Kanatani A; Nakagawa T; Kawai T; Naito A; Sato Y; Yoshida K; Nozaki K; Nagata M; Yamada Y; Azuma T; Suzuki M; Fujimura T; Fukuhara H; Nishimatsu H; Kume H; Igawa Y; Homma Y
Clin Genitourin Cancer; 2015 Apr; 13(2):e107-12. PubMed ID: 25456839
[TBL] [Abstract][Full Text] [Related]
11. The role of systemic chemotherapy in advanced bladder cancer.
van Groeningen CJ; Stoter G
Prog Clin Biol Res; 1984; 153():381-93. PubMed ID: 6382283
[No Abstract] [Full Text] [Related]
12. Prognostic significance of adjuvant cisplatin-based combination chemotherapy following radical cystectomy in patients with invasive bladder cancer.
Muramaki M; Miyake H; Kurahashi T; Takenaka A; Inoue TA; Fujisawa M
Int J Urol; 2008 Apr; 15(4):314-8. PubMed ID: 18380818
[TBL] [Abstract][Full Text] [Related]
13. Biomarker in Cisplatin-Based Chemotherapy for Urinary Bladder Cancer.
Ecke TH
Adv Exp Med Biol; 2015; 867():293-316. PubMed ID: 26530373
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant chemotherapy: a new treatment paradigm for muscle-invasive bladder cancer.
Herr HW
Eur Urol; 2009 Feb; 55(2):303-5; discussion 305-6. PubMed ID: 18995950
[No Abstract] [Full Text] [Related]
15. Predictive biomarkers for drug response in bladder cancer.
Yoshida T; Kates M; Fujita K; Bivalacqua TJ; McConkey DJ
Int J Urol; 2019 Nov; 26(11):1044-1053. PubMed ID: 31370109
[TBL] [Abstract][Full Text] [Related]
16. Adjuvant cisplatin-based combined chemotherapy for lymph node (LN)-positive urothelial carcinoma of the bladder (UCB) after radical cystectomy (RC): a retrospective international study of >1500 patients.
Lucca I; Rouprêt M; Kluth L; Rink M; Tilki D; Fajkovic H; Kassouf W; Hofbauer SL; de Martino M; Karakiewicz PI; Briganti A; Trinh QD; Seitz C; Fritsche HM; Burger M; Lotan Y; Kramer G; Shariat SF; Klatte T
BJU Int; 2015 May; 115(5):722-7. PubMed ID: 24905084
[TBL] [Abstract][Full Text] [Related]
17. Metallothionein in bladder cancer: correlation of overexpression with poor outcome after chemotherapy.
Wülfing C; van Ahlen H; Eltze E; Piechota H; Hertle L; Schmid KW
World J Urol; 2007 Apr; 25(2):199-205. PubMed ID: 17253087
[TBL] [Abstract][Full Text] [Related]
18. Overview of systemic treatment of bladder cancer and results with M-VAC therapy.
Yagoda A
Prog Clin Biol Res; 1990; 350():87-99. PubMed ID: 2201047
[TBL] [Abstract][Full Text] [Related]
19. [Organ-preserving treatment of bladder cancer with combined radiochemotherapy: Do patients profit from additional neoadjuvant chemotherapy?].
Diestelhorst A; Dunst J
Strahlenther Onkol; 1999 Aug; 175(8):414-5. PubMed ID: 10481776
[No Abstract] [Full Text] [Related]
20. Emmprin and survivin predict response and survival following cisplatin-containing chemotherapy in patients with advanced bladder cancer.
Als AB; Dyrskjøt L; von der Maase H; Koed K; Mansilla F; Toldbod HE; Jensen JL; Ulhøi BP; Sengeløv L; Jensen KM; Orntoft TF
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4407-14. PubMed ID: 17671123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
